These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1295 related items for PubMed ID: 28346656

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S.
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [Abstract] [Full Text] [Related]

  • 4. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    Tekatli H, van 't Hof S, Nossent EJ, Dahele M, Verbakel WFAR, Slotman BJ, Senan S.
    J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
    [Abstract] [Full Text] [Related]

  • 5. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2015 Jun 01; 92(2):325-31. PubMed ID: 25841625
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):e551-5. PubMed ID: 22417800
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, Senan S.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):348-53. PubMed ID: 22104360
    [Abstract] [Full Text] [Related]

  • 9. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18FDG-PET/CT.
    Mazzola R, Fiorentino A, Di Paola G, Giaj Levra N, Ricchetti F, Fersino S, Tebano U, Pasetto S, Ruggieri R, Salgarello M, Alongi F.
    J Thorac Oncol; 2017 Mar 01; 12(3):547-555. PubMed ID: 28126325
    [Abstract] [Full Text] [Related]

  • 10. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.
    Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, Quon A, Le QT, Diehn M, Loo BW.
    Lung Cancer; 2012 Dec 01; 78(3):219-24. PubMed ID: 23009727
    [Abstract] [Full Text] [Related]

  • 11. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN, Medbery C, Sharma S, Pablo J, Kimsey F, Perry D, Muacevic A, Mahadevan A.
    Radiat Oncol; 2015 May 15; 10():113. PubMed ID: 25975848
    [Abstract] [Full Text] [Related]

  • 12. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
    McDermott RL, Mihai A, Dunne M, Keys M, O'Sullivan S, Thirion P, ElBeltagi N, Armstrong JG.
    Clin Oncol (R Coll Radiol); 2021 May 15; 33(5):292-299. PubMed ID: 33309479
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.
    Katoh N, Soda I, Tamamura H, Takahashi S, Uchinami Y, Ishiyama H, Ota K, Inoue T, Onimaru R, Shibuya K, Hayakawa K, Shirato H.
    Radiat Oncol; 2017 Jan 05; 12(1):3. PubMed ID: 28057036
    [Abstract] [Full Text] [Related]

  • 14. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O'Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, Hahn SM, Heymach JV, Rice DC, Chang JY.
    JAMA Netw Open; 2018 Aug 03; 1(4):e181390. PubMed ID: 30646121
    [Abstract] [Full Text] [Related]

  • 15. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse.
    Loganadane G, Martinetti F, Mercier O, Krhili S, Riet FG, Mbagui R, To H, Le Péchoux C, Levy A.
    Cancer Treat Rev; 2016 Nov 03; 50():240-246. PubMed ID: 27768919
    [Abstract] [Full Text] [Related]

  • 16. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vanevski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Solomon B, TROG 09.02 CHISEL investigators.
    Lancet Oncol; 2019 Apr 03; 20(4):494-503. PubMed ID: 30770291
    [Abstract] [Full Text] [Related]

  • 17. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I, Poon I, Yeung L, Erler D, Kim A, Keller B, Lochray F, Jain S, Soliman H, Cheung P.
    Clin Oncol (R Coll Radiol); 2014 Nov 03; 26(11):713-9. PubMed ID: 25085765
    [Abstract] [Full Text] [Related]

  • 18. A Histologic Basis for the Efficacy of SBRT to the lung.
    Woody NM, Stephans KL, Andrews M, Zhuang T, Gopal P, Xia P, Farver CF, Raymond DP, Peacock CD, Cicenia J, Reddy CA, Videtic GM, Abazeed ME.
    J Thorac Oncol; 2017 Mar 03; 12(3):510-519. PubMed ID: 28017592
    [Abstract] [Full Text] [Related]

  • 19. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC.
    van den Berg LL, Klinkenberg TJ, Groen HJM, Widder J.
    J Thorac Oncol; 2015 May 03; 10(5):826-831. PubMed ID: 25629639
    [Abstract] [Full Text] [Related]

  • 20. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
    Lee DS, Kim YS, Yoo IeR, Kang YN, Kim SJ, Oh JK, Kim YK, Wang YP, Park JG, Kang JH, Han DH, Ahn MI, Lee KY.
    Lung Cancer; 2013 May 03; 80(2):172-8. PubMed ID: 23489556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.